Bioavailability of KBP-5074 Tablet vs Capsule Formulations

Summary

This is an open-label, partial crossover, single-dose study to evaluate the pharmacokinetics (PK), dose proportionality, and safety/tolerability of tablet versus capsule formulations of KBP-5074 in healthy subjects. The study is designed to evaluate the PK of a new tablet formulation versus that of the current capsule formulation. Data derived from this study, in addition to preclinical data and chemistry, manufacturing, and controls, will provide a basis for dose selection in future studies.

Timeline

Start

2017-10-26

Primary completion

2017-11-22

Completion

2017-12-19

Drugs

Indications

No indication recorded.